Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platelet Reactivity Clear all
Completed No phase listed Observational Accepts healthy volunteers

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

NCT03746782
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Flow Cytrometry; Thrombin Generation Assay
Diagnostic Test
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational

Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

NCT04668495
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Timeline
2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 18, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dried Cabernet Grapes and Cardiovascular Risk Markers

NCT03065166
View directory record Official record
Conditions
Healthy, Postmenopausal Women
Interventions
Raisin Treatment, Bagel Control
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 18, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation

NCT05967741
View directory record Official record
Conditions
Platelet Aggregation, Spontaneous, Vascular Thrombosis
Interventions
Erythritol, Aspartame
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Not listed No phase listed Observational

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

NCT03615846
View directory record Official record
Conditions
Platelet Aggregation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 18, 2026, 5:28 AM EDT
Terminated No phase listed Observational

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

NCT04125290
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Pueblo, Colorado • Bridgeton, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 18, 2026, 5:28 AM EDT
Recruiting Phase 4 Interventional

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational

Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention

NCT01796873
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
45 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational

Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients

NCT00460122
View directory record Official record
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 18, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 18, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet Reactivity With Fentanyl, Morphine, or no Narcotic

NCT05367336
View directory record Official record
Conditions
Fentanyl, Platelet Reactivity
Interventions
Morphine, Fentanyl
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 18, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607
View directory record Official record
Conditions
Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac Tromethamine 30 MG/ML, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

NCT03258281
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational

Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine

NCT01152229
View directory record Official record
Conditions
Platelet Aggregation, Bleeding
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Sep 18, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Blood draw only
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 18, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

ECMO Hemostatic Transfusions in Children

NCT05796557
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Thromboembolism, Transfusion Adverse Reaction
Interventions
Platelet Transfusion
Biological
Lead sponsor
Yale University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 18, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 5:28 AM EDT
Completed No phase listed Observational

Platelet Reactivity After CABG

NCT01793597
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 18, 2026, 5:28 AM EDT
Not listed No phase listed Observational

African-American Pharmacogenetics

NCT01408121
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 18, 2026, 5:28 AM EDT